Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Revance Therapeutics (NQ: RVNC ) 6.580 +0.010 (+0.15%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Revance Therapeutics < Previous 1 2 ... 7 8 9 10 11 12 13 14 Next > 10 Biggest Price Target Changes For Wednesday October 13, 2021 MKM Partners raised the price target on Continental Resources, Inc. (NYSE: Via Benzinga The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal October 13, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... Via Benzinga Exposures Product Safety 45 Biggest Movers From Yesterday October 13, 2021 Gainers ESSTech Inc (NYSE: GWH) shares surged 128.4% to close at $23.80 onTuesday. ESS Inc, the Bill Gates-backed battery maker went public on the NewYork Stock Exchange on... Via Benzinga The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO August 05, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... Via Benzinga Earnings Scheduled For May 10, 2021 May 10, 2021 Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report... Via Benzinga Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021 October 12, 2021 From Revance Therapeutics, Inc. Via Business Wire Revance Announces the Launch of OPUL™, the First-of-its-Kind Relational Commerce Platform for Aesthetic Practices October 11, 2021 From Revance Therapeutics, Inc. Via Business Wire Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021 September 16, 2021 From Revance Therapeutics, Inc. Via Business Wire Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting September 10, 2021 From Revance Therapeutics, Inc. Via Business Wire How Bad Are Revance Therapeutics's Earnings? | Return On Capital Employed September 03, 2021 Revance Therapeutics (NASDAQ:RVNC) brought in sales totaling $18.80 million during Q2 according to data provided by Benzinga Pro.However, earnings decreased 0.46%, resulting in a... Via Benzinga Revance to Participate in the Wells Fargo Securities Healthcare Conference September 02, 2021 From Revance Therapeutics, Inc. Via Business Wire Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery September 01, 2021 From Revance Therapeutics, Inc. Via Business Wire Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update August 05, 2021 From Revance Therapeutics, Inc. Via Business Wire Revance to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021 July 29, 2021 From Revance Therapeutics, Inc. Via Business Wire 18 Key Biopharma Catalysts To Keep An Eye On In Q3 July 10, 2021 Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Here is a look at some catalysts for the biopharam sector in the... Via Talk Markets 18 Key Biopharma Catalysts To Keep An Eye On In Q3 July 10, 2021 Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne... Via Benzinga The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs August 01, 2021 Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... Via Benzinga Exposures Product Safety Looking Into Revance Therapeutics's Return On Capital Employed June 24, 2021 Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $13.30 million. Earnings fell to a loss of $70.01 million, resulting in a 10.21% decrease from last quarter. Revance... Via Benzinga Looking Into Revance Therapeutics's Return On Capital Employed June 08, 2021 Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $13.30 million. Earnings fell to a loss of $70.01 million, resulting in a 10.21% decrease from last quarter. In Q4, Revance... Via Benzinga Revance to Participate in Upcoming Virtual Healthcare Conferences May 26, 2021 From Revance Therapeutics, Inc. Via Business Wire Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection May 26, 2021 From Revance Therapeutics, Inc. Via Business Wire Recap: Revance Therapeutics Q1 Earnings May 10, 2021 Shares of Revance Therapeutics (NASDAQ:RVNC) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 6.09% over the... Via Benzinga Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update May 10, 2021 From Revance Therapeutics, Inc. Via Business Wire Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021 May 03, 2021 From Revance Therapeutics, Inc. Via Business Wire Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal May 01, 2021 CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge will make a $10 million... Via Talk Markets Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA’s 24-Week Long Duration Profile Across Multiple Female Age Cohorts April 27, 2021 From Revance Therapeutics, Inc. Via Business Wire The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings May 09, 2021 Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... Via Benzinga Exposures COVID-19 Product Safety Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma April 27, 2021 From Revance Therapeutics, Inc. Via Business Wire Revance to Present Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Fillers at American Academy of Dermatology VMX Meeting 2021 April 23, 2021 From Revance Therapeutics Via Business Wire The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight April 10, 2021 Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of... Via Benzinga Exposures Product Safety < Previous 1 2 ... 7 8 9 10 11 12 13 14 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.